+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hidradenitis Suppurativa - Pipeline Review, H1 2020

  • ID: 4911712
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 216 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • CSL Ltd
  • Incyte Corp
  • NeuClone Pty Ltd
  • Pharmapraxis
  • MORE
Hidradenitis Suppurativa - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa - Pipeline Review, H1 2020, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.

Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 13, 4, 5 and 5 respectively.

Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • CSL Ltd
  • Incyte Corp
  • NeuClone Pty Ltd
  • Pharmapraxis
  • MORE
  • Introduction
  • Hidradenitis Suppurativa - Overview
  • Hidradenitis Suppurativa - Therapeutics Development
  • Hidradenitis Suppurativa - Therapeutics Assessment
  • Hidradenitis Suppurativa - Companies Involved in Therapeutics Development
  • Hidradenitis Suppurativa - Drug Profiles
  • Hidradenitis Suppurativa - Dormant Projects
  • Hidradenitis Suppurativa - Discontinued Products
  • Hidradenitis Suppurativa - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Hidradenitis Suppurativa, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Hidradenitis Suppurativa - Pipeline by UCB SA, H1 2020
  • Hidradenitis Suppurativa - Dormant Projects, H1 2020
  • Hidradenitis Suppurativa - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Hidradenitis Suppurativa, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Alvotech ehf
  • Amgen Inc
  • AstraZeneca Plc
  • ChemoCentryx Inc
  • CSL Ltd
  • Foamix Pharmaceuticals Ltd
  • Ichnos Sciences Inc
  • Immunwork Inc
  • Incyte Corp
  • InflaRx NV
  • Innovation Pharmaceuticals Inc
  • InSight Biopharmaceuticals Ltd
  • Johnson & Johnson
  • NeuClone Pty Ltd
  • Novartis AG
  • Pfizer Inc
  • Pharmapraxis
  • Siam Bioscience Co Ltd
  • Staidson (Beijing) Biopharmaceuticals Co Ltd
  • UCB SA
Note: Product cover images may vary from those shown
Adroll
adroll